After considering the feedback from consultation, the Appraisal Committee has prepared a Final Appraisal Determination (FAD) on cabozantinib for treating medullary thyroid cancer [ID56] and submitted it to the Institute.

The FAD has been sent to consultees for this appraisal who have 15 working days to consider whether they wish to appeal against it and/or notify us of any factual errors.  The FAD has been sent to commentators for information, who can consider notifying us of any factual errors only. Subject to any appeal by consultees, the FAD may be used as the basis for the Institute's guidance on the use of the appraised technology in the NHS in England.

The scope for this technology appraisal includes vandetanib. NICE is not currently in a position to release any recommendations on vandetanib. A separate document with the committee’s recommendations on vandetanib will be released at a later date.

For transparency, we have included the documents considered by the committee for vandetanib, even though we are not releasing any recommendations for this technology at this stage.

Please note that the appeal period for this appraisal will close at 5pm, 1 March 2018.

This page was last updated: